Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score >= 50% treated with front-line pembrolizumab-MedSci.cn

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score >= 50% treated with front-line pembrolizumab

Friedlaender, A; Metro, G; Signorelli, D; Gili, A; Economopoulou, P; Roila, F; Banna, G; De Toma, A; Camerini, A; Christopoulou, A; Lo Russo, G; Banini, M; Galetta, D; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Mountzios, G; Garassino, MC; Addeo, A

Addeo, A (corresponding author), Geneva Univ Hosp, Dept Oncol, Geneva, Switzerland.

Abstract

Objectives:We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treate......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score >= 50% treated with front-line pembrolizumab

科室

工具

服务